Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Core Insights - Aprea Therapeutics, Inc. reported financial results for Q3 2025, highlighting clinical progress in its WEE1 and ATR inhibitor programs, with cash runway extending into Q4 2026 [1][2]. Clinical Development - The ongoing ACESOT-1051 trial for APR-1051 (WEE1 kinase inhibitor) shows promising early signs of anti-tumor activity, with 3 out of 4 patients achieving stable disease at the 100 mg once daily dose [2][4]. - APR-1051 has advanced to the 150 mg once daily cohort as part of the dose escalation strategy [2][4]. - ATRN-119 (ATR kinase inhibitor) has identified a recommended Phase 2 dose of 1,100 mg once daily, with plans to explore combination strategies with radiation or checkpoint inhibitors [2][9]. Financial Performance - As of September 30, 2025, Aprea reported cash and cash equivalents of $13.7 million, down from $22.8 million at the end of 2024 [9][13]. - The company recorded an operating loss of $3.1 million for Q3 2025, an improvement from a $4.1 million loss in Q3 2024 [9][16]. - Research and Development (R&D) expenses decreased to $1.6 million in Q3 2025 from $2.8 million in the same quarter of 2024, primarily due to reduced study startup costs [9][16]. Business Strategy - Aprea is focusing on a differentiated DNA damage response (DDR) approach to treat cancers with specific vulnerabilities, particularly those over-expressing Cyclin E [5][8]. - The company is considering future studies of APR-1051 in combination with checkpoint inhibitors to address unmet medical needs across distinct patient populations [5][9].